Description

PT-141 (Bremelanotide) — FDA-Approved Melanocortin Agonist Research Compound

PT-141 — also known by its clinical name Bremelanotide — is one of the few research peptides that has completed the full path to FDA approval. It’s the active ingredient in Vyleesi, approved in 2019 for hypoactive sexual desire disorder in premenopausal women. That regulatory history makes it one of the most thoroughly documented compounds in the melanocortin research space.

What makes PT-141 distinct from other compounds in this category is its mechanism: it works through the central nervous system rather than the peripheral vascular system. It activates melanocortin receptors (specifically MC3R and MC4R) in the brain’s hypothalamus — a region involved in a broad range of regulatory functions. This CNS-pathway approach is what separates it pharmacologically from vasodilatory agents.

Research on PT-141 spans melanocortin receptor pharmacology, dopaminergic pathway modulation, and hypothalamic signaling. Its completed Phase II and Phase III clinical trial record provides researchers with a robust documented pharmacokinetic and safety profile to work from.

Best For: Cognitive; Wellness Signaling

Category: Cognitive / Neuro

For Research Use Only (RUO). Not for human or veterinary use. Not a drug. Not intended to diagnose, treat, cure, or prevent any disease.